Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Cue Biopharma, Inc.NASDAQ: CUE
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $11.05M fell 13.1% year over year, behind the +6.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 44.7% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Operating expenses amounted to 196.6% of revenue in FY2025, down 350.3 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.1% toward the trailing-twelve-month pace of +6.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 53.99M USD
- Year-over-year change
- +6.3%
- 4-year CAGR
- -2.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.99M | +6.3% |
| FY2024 | 2024-12-31 | 50.79M | +159.9% |
| FY2023 | 2023-12-31 | 19.54M | -64.1% |
| FY2022 | 2022-12-31 | 54.47M | -9.9% |
| FY2021 | 2021-12-31 | 60.43M | — |
Operating Expenses vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 operating expenses of $52.24M is the 3rd highest of the 7 companies compared; the peer median is $27.15M.
- Its year-over-year change of +6.3% is the 2nd highest of 7, against a peer median of -31.6%.
- Operating expenses amounts to 159.6% of revenue for CUE, versus a peer median of 999.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Mar 2026 | $52.24M | +6.3% | -0.3% | 159.6% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| Peer median (excluding CUE) | $27.15M | -31.6% | -16.8% | 999.7% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Cost of Revenue | (1.78M) | 0 | 38.1M | 0 | 0 |
| Gross Profit | 16.72M | 1.25M | (32.61M) | 9.29M | 27.47M |
| Gross Margin | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| Research & Development | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| Selling, General & Admin | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| Operating Expenses | 60.43M | 54.47M | 19.54M | 50.79M | 53.99M |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 3.48M |
| EBITDA | (45.44M) | (50.49M) | (46.05M) | (37.53M) | (22.27M) |
| EBITDA Margin | -304.1% | -4055.5% | -838.8% | -404.1% | -81.1% |
| Operating Income | (43.71M) | (53.23M) | (52.15M) | (41.5M) | (26.52M) |
| Operating Margin | -292.6% | -4275.1% | -949.9% | -446.9% | -96.6% |
| Interest Income | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income / Expenses | 45.9K | 215K | 1.42M | 826K | 419K |
| Income Before Tax | (43.67M) | (53.01M) | (50.73M) | (40.67M) | (26.1M) |
| Pre-Tax Margin | -292.3% | -4257.8% | -924.1% | -438.0% | -95.0% |
| Income Tax Expense | 495K | 0 | 0 | 0 | 500K |
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Net Margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (Basic) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| EPS (Diluted) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| Weighted Avg Shares | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Weighted Avg Shares (Diluted) | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.